Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms

Journal of the Formosan Medical Association

Volumn 109, Issue 10, 2010, Pages 702-708

  Ho, Chen Hsun ^a,b   Chang, Ting Chen ^a   Lin, Ho Hsiung ^a   Liu, Shih Ping ^a   Huang, Kuo How ^a   Yu, Hong Jeng ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Antimuscarinic agents; Overactive bladder; Solifenacin; Tolterodine

Indexed keywords

SOLIFENACIN; TOLTERODINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART PALPITATION; HICCUP; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; OPEN STUDY; OVERACTIVE BLADDER; PATIENT ASSESSMENT; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; URINARY URGENCY; URINE INCONTINENCE; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; CRESOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; PROSPECTIVE STUDIES; QUINUCLIDINES; TAIWAN; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; URINATION;

EID: 77958115871     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/S0929-6646(10)60114-3     Document Type: Article

References (22)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003, 61:37-49.
2. Chen GD, Lin TL, Hu SW, et al. Prevalence and correlation of urinary incontinence and overactive bladder in Taiwanese women. Neurourol Urodyn 2003, 22:109-117.
3. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006, 50:1306-1315.
4. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003, 20:327-336.
5. Abrams P, Kelleher CJ, Kerr LA, et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000, 6:S580-S590.
6. Brown JS, McGhan WF, Chokroverty S Comorbidities associated with overactive bladder. Am J Manag Care 2000, 6:S574-S579.
7. Wagner TH, Hu TW, Bentkover J, et al. Health-related consequences of overactive bladder. Am J Manag Care 2002, 8:S598-S607.
8. Andersson KE Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004, 3:46-53.
9. Hegde SS, Eglen RM Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci 1999, 64:419-428.
10. Stahl MM, Ekstrom B, Sparf B, et al. Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 1995, 14:647-655.
11. Appell RA Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997, 50:90-99.
12. Cardozo L, Lisec M, Millard R, et al. Randomized, doubleblind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004, 172:1919-1924.
13. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succi-nate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005, 48:464-470.
14. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004, 93:303-310.
15. Coyne KS, Matza LS, Kopp Z, et al. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006, 49:1079-1086.
16. World Health Organization International monitoring of adverse reactions to drugs: adverse reaction terminology 1992, WHO Collaborating Centre for International Drug Monitoring, Uppsala.
17. Abrams P, Andersson KE Muscarinic receptor antagonists for overactive bladder. BJU Int 2007, 100:987-1006.
18. Chess-Williams R Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol 2002, 22:133-145.
19. Andersson KE Bladder activation: afferent mechanisms. Urology 2002, 59:43-50.
20. Finney SM, Andersson KE, Gillespie JI, et al. Antimus-carinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?. BJU Int 2006, 98:503-507.
21. Chapple C, Khullar V, Gabriel Z, et al. The effects of anti-muscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005, 48:5-26.
22. Staskin DR, MacDiarmid SA Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. Am J Med 2006, 119:9-15.